These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

354 related items for PubMed ID: 28619071

  • 21. Liver-Directed AAV8 Booster Vaccine Expressing Plasmodium falciparum Antigen Following Adenovirus Vaccine Priming Elicits Sterile Protection in a Murine Model.
    Shahnaij M, Iyori M, Mizukami H, Kajino M, Yamagoshi I, Syafira I, Yusuf Y, Fujiwara K, Yamamoto DS, Kato H, Ohno N, Yoshida S.
    Front Immunol; 2021; 12():612910. PubMed ID: 34248928
    [Abstract] [Full Text] [Related]

  • 22. Adjuvant and carrier protein-dependent T-cell priming promotes a robust antibody response against the Plasmodium falciparum Pfs25 vaccine candidate.
    Radtke AJ, Anderson CF, Riteau N, Rausch K, Scaria P, Kelnhofer ER, Howard RF, Sher A, Germain RN, Duffy P.
    Sci Rep; 2017 Jan 16; 7():40312. PubMed ID: 28091576
    [Abstract] [Full Text] [Related]

  • 23. Functional comparison of Plasmodium falciparum transmission-blocking vaccine candidates by the standard membrane-feeding assay.
    Miura K, Takashima E, Deng B, Tullo G, Diouf A, Moretz SE, Nikolaeva D, Diakite M, Fairhurst RM, Fay MP, Long CA, Tsuboi T.
    Infect Immun; 2013 Dec 16; 81(12):4377-82. PubMed ID: 24042109
    [Abstract] [Full Text] [Related]

  • 24.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 25. Safety and immunogenicity of a plant-produced Pfs25 virus-like particle as a transmission blocking vaccine against malaria: A Phase 1 dose-escalation study in healthy adults.
    Chichester JA, Green BJ, Jones RM, Shoji Y, Miura K, Long CA, Lee CK, Ockenhouse CF, Morin MJ, Streatfield SJ, Yusibov V.
    Vaccine; 2018 Sep 18; 36(39):5865-5871. PubMed ID: 30126674
    [Abstract] [Full Text] [Related]

  • 26. A region of Plasmodium falciparum antigen Pfs25 that is the target of highly potent transmission-blocking antibodies.
    Stowers AW, Keister DB, Muratova O, Kaslow DC.
    Infect Immun; 2000 Oct 18; 68(10):5530-8. PubMed ID: 10992450
    [Abstract] [Full Text] [Related]

  • 27. Development of a Pfs25-EPA malaria transmission blocking vaccine as a chemically conjugated nanoparticle.
    Shimp RL, Rowe C, Reiter K, Chen B, Nguyen V, Aebig J, Rausch KM, Kumar K, Wu Y, Jin AJ, Jones DS, Narum DL.
    Vaccine; 2013 Jun 19; 31(28):2954-62. PubMed ID: 23623858
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 30. Structural vaccinology of malaria transmission-blocking vaccines.
    Patel PN, Tolia N.
    Expert Rev Vaccines; 2021 Feb 19; 20(2):199-214. PubMed ID: 33430656
    [Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. A Plasmodium Promiscuous T Cell Epitope Delivered within the Ad5 Hexon Protein Enhances the Protective Efficacy of a Protein Based Malaria Vaccine.
    Fonseca JA, Cabrera-Mora M, Kashentseva EA, Villegas JP, Fernandez A, Van Pelt A, Dmitriev IP, Curiel DT, Moreno A.
    PLoS One; 2016 Feb 19; 11(4):e0154819. PubMed ID: 27128437
    [Abstract] [Full Text] [Related]

  • 33. Assessment of Pfs25 expressed from multiple soluble expression platforms for use as transmission-blocking vaccine candidates.
    Lee SM, Wu CK, Plieskatt J, McAdams DH, Miura K, Ockenhouse C, King CR.
    Malar J; 2016 Aug 11; 15(1):405. PubMed ID: 27515826
    [Abstract] [Full Text] [Related]

  • 34. Functional Characterization and Comparison of Plasmodium falciparum Proteins as Targets of Transmission-blocking Antibodies.
    Nikolaeva D, Illingworth JJ, Miura K, Alanine DGW, Brian IJ, Li Y, Fyfe AJ, Da DF, Cohuet A, Long CA, Draper SJ, Biswas S.
    Mol Cell Proteomics; 2020 Jan 11; 19(1):155-166. PubMed ID: 29089373
    [Abstract] [Full Text] [Related]

  • 35.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 36. Maintaining immunogenicity of blood stage and sexual stage subunit malaria vaccines when formulated in combination.
    Parzych EM, Miura K, Long CA, Burns JM.
    PLoS One; 2020 Jan 11; 15(4):e0232355. PubMed ID: 32348377
    [Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 39. Plasmodium falciparum: immunogenicity of alum-adsorbed clinical-grade TBV25-28, a yeast-secreted malaria transmission-blocking vaccine candidate.
    Gozar MM, Muratova O, Keister DB, Kensil CR, Price VL, Kaslow DC.
    Exp Parasitol; 2001 Feb 11; 97(2):61-9. PubMed ID: 11281702
    [Abstract] [Full Text] [Related]

  • 40. Strain-transcending immune response generated by chimeras of the malaria vaccine candidate merozoite surface protein 2.
    Krishnarjuna B, Andrew D, MacRaild CA, Morales RA, Beeson JG, Anders RF, Richards JS, Norton RS.
    Sci Rep; 2016 Feb 11; 6():20613. PubMed ID: 26865062
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 18.